Find Press/Media

Search results

• Nivolumab/cabozantinib shows improvements in long-term survival for RCC

  Mauricio Burotto

  19/02/23

  2 items of Media coverage

  Press/Media

• How Covid vaccination is coming in 2023

  Maria Luz Endeiza

  18/02/23

  1 item of Media coverage

  Press/Media

• Eliminalia's ruses to clean up the image of politicians, businessmen and criminals

  Francisco Espinoza

  17/02/23

  1 item of Media coverage

  Press/Media

• Positive results for Ipsen 's Cabometyx in combination with nivolumab

  Mauricio Burotto

  17/02/23

  1 item of Media coverage

  Press/Media

• Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms

  Mauricio Burotto

  16/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  16/02/23

  1 item of Media coverage

  Press/Media

• Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

  Mauricio Burotto

  16/02/23

  1 item of Media coverage

  Press/Media

• Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

  Mauricio Burotto

  15/02/23

  1 item of Media coverage

  Press/Media

• Opdivo-Cabometyx shows long-term effects in primary care of kidney cancer

  Mauricio Burotto

  15/02/23

  2 items of Media coverage

  Press/Media

• Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

  Mauricio Burotto

  15/02/23

  1 item of Media coverage

  Press/Media

• How many are retired, where are they playing: a look back at the Golden Generation that won the 2015 Copa América

  Manuel Pellegrini

  15/02/23

  1 item of Media coverage

  Press/Media

• Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

  Mauricio Burotto

  15/02/23

  1 item of Media coverage

  Press/Media

• Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Ipsen announces CheckMate 3-yr follow-up aRCC results

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  14/02/23

  2 items of Media coverage

  Press/Media

• Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  13/02/23 → 14/02/23

  17 items of Media coverage

  Press/Media

• Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  14/02/23

  2 items of Media coverage

  Press/Media

• Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  14/02/23

  1 item of Media coverage

  Press/Media

• Zoom a las causas y tiempos del Poder Judicial

  Rosa Gómez

  13/02/23

  1 Media contribution

  Press/Media

• Ipsen: Cabometyx in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  13/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  13/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

  Mauricio Burotto

  13/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  13/02/23

  1 item of Media coverage

  Press/Media

• Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma

  Mauricio Burotto

  13/02/23

  56 items of Media coverage

  Press/Media